Cellect Biotechnology Ltd (APOP) EPS Estimated At $-0.22

August 17, 2017 - By reb123z

 Cellect Biotechnology Ltd (APOP) EPS Estimated At $ 0.22

Wall Street await Cellect Biotechnology Ltd (TLV:APOP) to release earnings on September, 7. Analysts forecast earnings per share of $-0.22, down exactly $0.21 or 2,100.00 % from 2014’s $-0.01 EPS. After posting $-0.04 EPS for the previous quarter, Cellect Biotechnology Ltd’s analysts now forecast 450.00 % negative EPS growth. About 156,207 shares traded. Cellect Biotechnology Ltd (TLV:APOP) has 0.00% since August 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Cellect Biotechnology Ltd, formerly Cellect Biomed Ltd, is an Israel firm engaged in regenerative medicine through the development of products facilitating immune stem cell selection. The company has market cap of $133.25 million. The Company’s platform technology is based on the game changing perception that the functional properties of stem cells rather than appearance should be used for their identification, selection and utilization. It currently has negative earnings. The Company’s first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents.

More notable recent Cellect Biotechnology Ltd (TLV:APOP) news were published by: Rttnews.com which released: “Cellect Biotechnology Ltd. (APOP) Is Surging On Patent News” on January 12, 2017, also Marketwatch.com with their article: “6.31” published on July 29, 2016, Streetinsider.com published: “Cellect Biotechnology (APOP) Announces Positive Results of Clinical Trial of …” on February 21, 2017. More interesting news about Cellect Biotechnology Ltd (TLV:APOP) were released by: Fool.com and their article: “Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today” published on February 08, 2017 as well as Globenewswire.com‘s news article titled: “Cellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences …” with publication date: January 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.